新抗癌天然产物裂果薯总皂苷体外对肝癌细胞铁死亡相关基因表达的影响研究*

doi:10.3969/j.issn.1672-5069.2026.04.004

摘要/Abstract

摘要： 目的观察新抗癌天然产物裂果薯总皂苷(SSPH)对HepG2和Huh7肝癌细胞铁死亡相关基因谷胱甘肽过氧化物酶4(GPX4)、溶质载体家族7成员11(SLC7A11)和酰基辅酶A合成酶长链家族成员4(ACSL4)表达的影响。方法分别取HepG2和Huh7细胞,分为对照组(DMEM)和小(0.73 μM)、中(1.46 μM)、大剂量(2.91 μM)SSPH处理组。采用MTT法检测细胞增殖活性,采用苯啰啉比色法检测Fe²⁺浓度,采用荧光探针法检测活性氧(ROS)水平,采用qRT-PCR法检测GPX4、SLC7A11和ACSL4 mRNA水平,采用Western blot法检测对应蛋白表达。结果小、中和大剂量SSPH处理组HepG2和Huh7肝癌细胞增殖活性降低,且抑制作用呈剂量-时间依赖性(P<0.05);处理组HepG2细胞和Huh7细胞ROS水平均显著高于对照组(P<0.05),细胞Fe²⁺含量也均显著高于对照组(P<0.05);处理组HepG2细胞和Huh7细胞GPX4和SLC7A11 mRNA相对水平均显著低于对照组(P<0.05),而ACSL4 mRNA水平则显著高于对照组(P<0.05);处理组HepG2和Huh7细胞GPX4和SLC7A11表达比对照组显著下调(P<0.05),而ACSL4表达比对照组显著上调(P<0.05)。结论新抗癌天然产物SSPH可通过诱导肝癌细胞铁死亡发挥抗肝癌作用,其机制可能与调控ACSL4、GPX4和SLC7A11等铁死亡相关基因表达,促进细胞内ROS积累和Fe²⁺过载有关。

关键词: HepG2, Huh7, 裂果薯总皂苷, 谷胱甘肽过氧化物酶4, 溶质载体家族7成员11, 酰基辅酶A合成酶长链家族成员4, 铁死亡, 体外

Abstract: Objective The aim of this experiment was to investigate effects of schizocapsa plantaginea hance (SSPH), a new anti-cancer natural product, on expressions of ferroptosis-related genes, e.g., glutathione peroxidase 4 (GPX4), solute carrier family 7 member 11 (SLC7A11) and acyl-CoA synthase long-chain family member 4 (ACSL4) in HepG2 and Huh7 cells in vitro. Methods HepG2 and Huh7 cells were respectively divided into control (DMEM), low-dose (0.73 μM), medium-dose (1.46 μM) and high-dose (2.91 μM) SSPH-intervened groups. Cell proliferations were detected by MTT, supernatant Fe²⁺ concentration was determined by o-phenanthroline colorimetry, and reactive oxygen species (ROS) was assayed by fluorescence probe. GPX4, SLC7A11 and ACSL4 mRNA were detected by qRT-PCR and the corresponding protein expressions were detected by Western blot. Results HepG2 and Huh7 cell proliferation greatly in a dose-dependent manner inhibited in low-, medium- and high-dose SSPH-intervened groups as compared to in the control(P<0.05); supernatant ROS and Fe²⁺contents in SSPH-intervened HepG2 and Huh7 cells were significantly increased compared to in the control group (P<0.05);cell GPX4 and SLC7A11 mRNA relative levels in SSPH-intervened HepG2 and Huh7 cells decreased (P<0.05), while ACSL4 mRNA relative level increased greatly compared to in the control (P<0.05); cell GPX4 and SLC7A11 protein expression SSPH-intervened HepG2 and Huh7 cells weaken significantly(P<0.05), while ACSL4 protein expression intensified significantly compared to in the control group (P<0.05). Conclusion SSPH could exert anti-liver cancer effect by inducing ferroptosis in hepatoma cells, and the mechanism by which the intracellular ROS and Fe²⁺ were overloaded, might be related to regulation of ferroptosis-related genes, e.g., ACSL4, GPX4 and SLC7A11 expressions.

Key words: HepG2, Huh7 cells, Schizocapsa plantaginea hance, Glutathione peroxidase 4, Solute carrier family 7 member 11, Acyl-CoA synthase long-chain family member 4, Ferroptosis, In vitro

高文娟, 刘丽娜, 黄超群. 新抗癌天然产物裂果薯总皂苷体外对肝癌细胞铁死亡相关基因表达的影响研究^*[J]. 实用肝脏病杂志, 2026, 29(4): 493-496.

Gao Wenjuan, Liu Lina, Huang Chaoqun. Effects of schizocapsa plantaginea hance on expressions of ferroptosis-related genes in HepG2 and Huh7 cells in vitro[J]. Journal of Practical Hepatology, 2026, 29(4): 493-496.

参考文献

[1] Li HB, Huang L, Ni JY, et al. TraditionalChinese medicine in the treatment of adverse reactions after TACE for primary hepatic carcinoma: effect, mechanism, and potential advantages. Phytomedicine, 2024,135:156244.
[2] 谢晶美,刘浩,李安,等.动态增强MRI定量参数术前评估原发性肝癌患者临床分期研究.实用肝脏病杂志, 2024, 27(2):255-258.
[3] Yau T, Galle PR, Decaens T, et al. CheckMate 9DW investigators. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomized, phase 3 trial. Lancet, 2025,405(10492):1851-1864.
[4] Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol, 2023,20(12):864-884.
[5] 杜尚云,翁莉,武敏.TACE联合卡瑞利珠单抗治疗中晚期原发性肝癌患者临床疗效研究.实用肝脏病杂志, 2023, 26(1):116-119.
[6] Meixian L, Huan Z, Limin Z, et al. Saponin Ⅰ from Shuitianqi inhibits metastasis by negatively regulating the transforming growth factor-β1/Smad7 network and epithelial-mesenchymal transition in the intrahepatic metastasis Bagg's Albino/c mouse model. J Tradit Chin Med, 2024,44(4):642-651.
[7] Liu J, Luo Y, Chen S, et al. Deubiquitylase USP52 promotes bladder cancer progression by modulating ferroptosis through stabilizing SLC7A11/xCT. Adv Sci (Weinh), 2024, 11(45):e2403995.
[8] Ajoolabady A, Tang D, Kroemer G, et al. Ferroptosis in hepatocellular carcinoma: mechanisms and targeted therapy. Br J Cancer, 2023,128(2):190-205.
[9] He F, Zhang P, Liu J, et al. ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. J Hepatol, 2023,79(2):362-377.
[10] Capelletti MM, Manceau H, Puy H, et al. Ferroptosis in liver diseases: an overview. Int J Mol Sci,2020,21(14):4908.
[11] Zhou JL, Huang XY, Qiu HC, et al. SSPH I, a novel anti-cancer saponin, inhibits autophagy and induces apoptosis via ros accumulation and ERK1/2 signaling pathway in hepatocellular carcinoma cells. Onco Targets Ther, 2020,13:5979-5991.
[12] Hao X, Wang Y, Hou MJ, et al. Strong protection by bazedoxifene against chemically-induced ferroptotic neuronal death in vitro and in vivo. Cell Commun Signal, 2025,23(1):218.
[13] Lei M, Zhang YL, Huang FY, et al. Gankyrin inhibits ferroptosis through the p53/SLC7A11/GPX4 axis in triple-negative breast cancer cells. Sci Rep, 2023,13(1):21916.
[14] 田潭平,杨定华,宋新,等. TACE联合免疫和靶向综合治疗中晚期原发性肝癌患者临床效果研究.实用肝脏病杂志,2025,28(6):898-901.
[15] Liang Y, Meng J, Yu Z, et al. Ru single-atom nanozymes targeting ROS-ferroptosis pathways for enhanced endometrial regeneration in intrauterine adhesion therapy. Biomaterials, 2025,315:122923.
[16] Liang FG, Zandkarimi F, Lee J, et al. OPA1 promotes ferroptosis by augmenting mitochondrial ROS and suppressing an integrated stress response. Mol Cell, 2024, 84(16):3098-3114.e6.
[17] Jiang Y, Hui D, Pan Z, et al. Curcumin promotes ferroptosis in hepatocellular carcinoma via upregulation of ACSL4. J Cancer Res Clin Oncol, 2024,150(9):429.
[18] Hu J, Ghosh C, Khaket TP, et al. Dual targeting of BRAF V600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress.Bio Rxiv, 2025,27:661418.
[19] Chen Q, Zheng W, Guan J, et al. SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell Death Differ, 2023, 30(1):137-151.
[20] Wu D, Spencer CB, Ortoga L, et al. Histone lactylation-regulated METTL3 promotes ferroptosis via m6A-modification on ACSL4 in sepsis-associated lung injury. Redox Biol, 2024,74:103194.

新抗癌天然产物裂果薯总皂苷体外对肝癌细胞铁死亡相关基因表达的影响研究^*

Effects of schizocapsa plantaginea hance on expressions of ferroptosis-related genes in HepG2 and Huh7 cells in vitro

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	上官峰, 张梦曦, 王玉华. RIMS3通过促进GABA分泌介导Hep3B和MHCC97H肝癌细胞对仑法替尼耐药实验研究^*[J]. 实用肝脏病杂志, 2026, 29(3): 332-336.
[2]	李昂, 杨晓丹. DUSP10通过增强肝癌细胞干性促进对仑伐替尼耐药的实验研究^*[J]. 实用肝脏病杂志, 2025, 28(4): 493-496.
[3]	邓万玉, 黄子乐, 刘泽妍, 秦培毓, 刘娜. HepG2和HepG2.2.15细胞ENPP2/EZH2表达变化及其对细胞增殖和侵袭力的影响^*[J]. 实用肝脏病杂志, 2025, 28(4): 497-500.
[4]	李全维, 高明慧, 寇卜心, 柴梦音, 霍云飞, 豆双双, 庞丽君, 石英, 刘晓霓. p65通过调控脂代谢影响HepG2细胞增殖研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 173-177.
[5]	沈起艳, 张龙, 张艳琼, 张小雅, 王鲁文, 龚作炯. SIRT1激动剂CAY10602对急性肝衰竭小鼠肝损伤保护作用研究^*[J]. 实用肝脏病杂志, 2025, 28(1): 20-23.
[6]	路瑶, 焦谊, 古丽阿依木. 利拉鲁肽通过Sirt1/AMPK信号通路改善肝细胞脂肪变性机制研究^*[J]. 实用肝脏病杂志, 2024, 27(5): 673-676.
[7]	杨丽花, 丁凌, 张玉明. PTBD联合体外辅助胆汁入肠治疗恶性梗阻性黄疸患者疗效研究^*[J]. 实用肝脏病杂志, 2024, 27(4): 619-622.
[8]	石影, 李亚妮, 李红刚. HepG2细胞Six4蛋白表达对细胞增殖、迁移和上皮-间充质转化的影响[J]. 实用肝脏病杂志, 2024, 27(4): 635-637.
[9]	吴伟杰, 丁雯瑾, 杨蕊旭, 范建高. Notch抑制剂DAPT体外改善L02细胞脂肪变研究^*[J]. 实用肝脏病杂志, 2024, 27(1): 16-19.
[10]	仲金龙, 施琳. miR-556-3p通过调控PTEN/AKT信号通路影响肝细胞癌的转移活性^*[J]. 实用肝脏病杂志, 2023, 26(6): 781-784.
[11]	霍云飞, 寇卜心, 柴梦音, 豆双双, 高明慧, 石英, 刘晓霓. 体外靶向TP53BP2基因shRNA慢病毒载体的构建及功能鉴定^*[J]. 实用肝脏病杂志, 2023, 26(2): 164-168.
[12]	孙东磊, 郭金波, 王丹丹, 罗雨欣, 牛国超, 杨双双, 张晓岚. 间充质干细胞外泌体对体外肝星状细胞增殖和活化的影响[J]. 实用肝脏病杂志, 2023, 26(1): 11-14.
[13]	贺潇瑾, 李丹, 周青, 欧阳静, 田玉球, 谭英征. L02细胞乙型肝炎病毒X蛋白和SOCS-1基因水平研究^*[J]. 实用肝脏病杂志, 2022, 25(6): 772-775.
[14]	胡鹏蕴, 赵宏峰, 杨小伟, 史保宾. 新型促癌基因LSM11通过Wnt/β-catenin信号通路促进肝癌细胞增殖^*[J]. 实用肝脏病杂志, 2022, 25(5): 628-632.
[15]	张缨, 江龙委, 秦峰, 贾绍昌. LncRNA HOXD-AS1在斑马鱼异种移植模型对肝细胞癌细胞增殖和迁移能力的影响^*[J]. 实用肝脏病杂志, 2022, 25(4): 472-475.